NASDAQ:AUXL Auxilium Pharmaceuticals (AUXL) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free AUXL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume1.32 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Auxilium Pharmaceuticals alerts: Email Address Ad Awesomely, LLCAutomatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. About Auxilium Pharmaceuticals Stock (NASDAQ:AUXL)Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.Read More Ad Awesomely, LLCAutomatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. AUXL Stock News HeadlinesApril 17, 2024 | tmcnet.comElevated Signals and Auxilium Partner to Recover the $3.4 Trillion of Critical Minerals in Mining WasteJanuary 1, 2024 | investing.comAUX/ETH - Auxilium EthereumMay 5, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. September 14, 2023 | investing.comAUX/USD - Auxilium US DollarApril 22, 2023 | dailymail.co.uk'Male menopause is a myth'November 19, 2022 | finance.yahoo.comMarine Pharmaceuticals Market to grow by USD 1.56 Bn; Oncology to be the largest revenue generating segment - TechnavioSeptember 13, 2022 | thestreet.comWhy Auxilium Pharmaceutical (AUXL) Stock Is Down This MorningAugust 27, 2022 | thestreet.comAuxilium Pharmaceuticals' Slow Response to Endo Troubles InvestorsSee More Headlines Receive AUXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Auxilium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2014Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AUXL CUSIP05334D10 CIK1182129 Webwww.auxilium.com Phone+1-484-3215900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report AUXL Stock Analysis - Frequently Asked Questions How were Auxilium Pharmaceuticals' earnings last quarter? Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) announced its quarterly earnings data on Thursday, October, 30th. The biopharmaceutical company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.30. The biopharmaceutical company had revenue of $109.60 million for the quarter, compared to analysts' expectations of $101.02 million. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 EPS. What other stocks do shareholders of Auxilium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Auxilium Pharmaceuticals investors own include Royalty Pharma (RPRX), Yelp (YELP), AEGR (AEGR), Arctos NorthStar Acquisition (ANAC), MannKind (MNKD), Netflix (NFLX), Acorda Therapeutics (ACOR), Altaba (AABA), Agios Pharmaceuticals (AGIO) and Allergan (AGN). This page (NASDAQ:AUXL) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Auxilium Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
